Societal implications of the pharmacoeconomics of α1-antitrypsin deficiency

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 3, 2002, Pages 243-249

  Mullins, C Daniel ^a   Blatt, Lisa ^a   Wang, Junling ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

1 antitrypsin deficiency; Cost; genetic aerosol therapy; Pulmonary; Reimbursement

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; PUBLICATION; REIMBURSEMENT; REVIEW; SOCIAL ASPECT;

EID: 0036078175     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.3.243     Document Type: Review

References (31)

1. 1-antitrypsin deficiency
2. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group
3. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy
4. Alpha-1-antitrypsin deficiency: What next?
5. Augmentation therapy for severe alpha 1-antitrypsin deficiency: Is the jury still out on a trial?
6. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency
7. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin
8. Alpha 1-antitrypsin deficiency
9. Diagnosing alpha1-antitrypsin deficiency
10. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency
11. Strategies for aerosol therapy of α1-antitrypsin deficiency by the aerosol route
12. Cost-effectiveness of A1 replacement therapy in treatment of congenital chronic obstructive pulmonary disease
13. Should healthcare systems pay for replacement therapy in patients with A1 deficiency? A critical review and cost-effectiveness analysis
14. The Direct Medical Costs of Alpha 1-Antitrypsin Deficiency
15. Alpha sub 1-proteinase inhibitor (human) shortage. Letter to the editor
16. Alpha sub1-proteinase inhibitor (human) shortage. Letter to the editor
17. α1-Antitrypsin deficiency: Impact of genetic discovery on medicine and society
18. Demographics and impact of alpha 1-antitrypsin deficiency: Results of a mail survey
19. Inhalation of [123I] α1-protease inhibitor: Toward a new therapeutic concept of α1-protease inhibitor deficiency
20. Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency
21. Antineutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin
22. Fate of aerosolized recombinant DNA-produced α1-antitrypsin: Use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic important
23. The intrapulmonary half-life and safety of aerosolized α1-protease inhibitor in normal volunteers
24. Biotechnology: A special case for health technology assessment?